echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > NNP: Doxycycline in Neuropathic Lyme Disease, a Multicenter, Double-Blind, Randomized and Placebo-Controlled Trial

    NNP: Doxycycline in Neuropathic Lyme Disease, a Multicenter, Double-Blind, Randomized and Placebo-Controlled Trial

    • Last Update: 2022-10-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Lyme disease neuropathic (LNB) usually presents with painful meningeal radiculitis and/or cranial neuritis with discomfort and fatigue


    Recommendations regarding the duration of treatment are divided


    The trial was randomized, double-blind, placebo-controlled


    Research Process

    Secondary endpoints were CCS at 10 weeks and 12 months, CSF results at 6 months and 12 months, safety measured by blood tests (hematology values, kidney and liver function) at 2 months and 4 months Patients reported outcome measures (PROMs) and weekly reported side effects in a 10-week patient diary a few weeks after initiation of sexual and tolerable therapy


    Combined clinical scores for both treatment groups throughout the study

    A total of 121 patients were included


    The results showed no benefit of doxycycline treatment beyond 2 weeks


     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.